高瓴拟接盘！603259，28亿元大动作

Core Viewpoint - WuXi AppTec plans to sell assets to Hillhouse Capital for 2.8 billion yuan, which is expected to significantly boost the company's net profit in 2025 [2][20]. Group 1: Transaction Details - WuXi AppTec's wholly-owned subsidiary, Shanghai WuXi AppTec New Drug Development Co., Ltd., intends to transfer 100% equity of Shanghai Kande Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jishi Pharmaceutical Technology Co., Ltd. to companies established by Hillhouse Capital [9][12]. - The transaction is based on a benchmark equity transfer price of 2.8 billion yuan, with the final price to be determined by the financial conditions of the transferred companies and their performance from 2026 to 2028 [13][21]. Group 2: Financial Performance - For the first three quarters of 2025, WuXi AppTec reported a year-on-year increase in net profit attributable to shareholders of 84.84%, reaching 12.076 billion yuan, driven by a focus on the CRDMO business model and gains from the sale of shares in WuXi XDC Cayman Inc. [5][24]. - The net profit of Kande Hongyi for 2024 and the first three quarters of 2025 was -42.47 million yuan and -75.45 million yuan, respectively, while Jishi Pharmaceutical reported net profits of 313.13 million yuan and 162.79 million yuan for the same periods [15][19]. Group 3: Strategic Focus - The company aims to enhance its focus on the CRDMO business model, which includes drug discovery, laboratory testing, and process development and production services, to accelerate global capabilities and capacity deployment [24].